BidaskClub upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong sell rating to a sell rating in a research report released on Tuesday morning.

Several other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Wednesday, January 3rd. Stifel Nicolaus reaffirmed a buy rating on shares of LeMaitre Vascular in a research note on Sunday, October 29th. Canaccord Genuity decreased their price objective on shares of LeMaitre Vascular from $30.00 to $29.00 and set a hold rating on the stock in a research note on Friday, October 27th. Benchmark cut shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday, October 27th. Finally, First Analysis cut shares of LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 price objective on the stock. in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The stock has an average rating of Hold and an average target price of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) traded up $0.34 during trading on Tuesday, reaching $33.16. 79,240 shares of the company’s stock traded hands, compared to its average volume of 118,162. The company has a market capitalization of $630.80, a PE ratio of 42.51, a price-to-earnings-growth ratio of 2.53 and a beta of 0.54. LeMaitre Vascular has a 1 year low of $19.82 and a 1 year high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The firm had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.17 earnings per share. research analysts anticipate that LeMaitre Vascular will post 0.84 earnings per share for the current fiscal year.

In other news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $32.14, for a total transaction of $132,513.22. Following the transaction, the insider now directly owns 24,482 shares in the company, valued at $786,851.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 23.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of LeMaitre Vascular by 2.8% during the third quarter. Dimensional Fund Advisors LP now owns 995,747 shares of the medical instruments supplier’s stock worth $37,261,000 after purchasing an additional 27,515 shares in the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of LeMaitre Vascular by 51.2% during the third quarter. Conestoga Capital Advisors LLC now owns 854,644 shares of the medical instruments supplier’s stock worth $31,981,000 after purchasing an additional 289,575 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of LeMaitre Vascular by 23.5% during the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock worth $25,462,000 after purchasing an additional 155,249 shares in the last quarter. State Street Corp lifted its position in shares of LeMaitre Vascular by 25.2% during the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock worth $11,951,000 after purchasing an additional 77,009 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. lifted its position in shares of LeMaitre Vascular by 10.6% during the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 356,517 shares of the medical instruments supplier’s stock worth $11,351,000 after purchasing an additional 34,162 shares in the last quarter. Institutional investors own 69.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “LeMaitre Vascular (LMAT) Rating Increased to Sell at BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/lemaitre-vascular-lmat-rating-increased-to-sell-at-bidaskclub/1814492.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.